Blog
/
4
min read
/
October 9, 2023

Helping millions to their right to good mental health

Good mental health is a universal human right — but most don’t have access to quality care. Here’s how you can tackle this issue, starting within your organization.

In recognition of World Mental Health Day, the World Health Organization’s 2023 campaign reminds us that mental health is a universal human right, including the right to accessible, acceptable, and good-quality care. Unfortunately, this isn’t the reality for many struggling with access challenges.

Let’s look at the barriers to quality care that many face in the US specifically and the steps you can take within your organization to address them today.  

Acknowledging barriers to care

When it comes to mental health treatment, medication has long been the default care method, despite concerns over side effects and physical dependence. However, 75% of patients say they would prefer a non-drug option to address their mental health conditions. Those seeking in-person therapy are met with access challenges due to a shortage of providers taking on exhausting patient loads:

  • 37% of people in the US are living in areas with a mental health provider shortage.
  • The average wait time to see a licensed mental health provider is eight weeks.
  • Up to 80% of children, youth, and young adults do not receive adequate treatment for their mental health conditions.

And, of course, we need to take into account that mental health care is expensive and unsustainable in the long term for many. All of these factors aside — some people may still choose not to seek care due to the stigma around mental health.

Implementing positive change in your organization

So, what can you do to ensure your organization has access to necessary care for their mental health concerns despite these challenges? There are a number of steps you can take to start implementing positive change today:

  • Take a close look at your benefits package and evaluate if it is serving the mental and emotional needs of your organization.
  • Be open and responsive to feedback and listen when people ask for support.
  • Identify warning signs of poor mental health, like trends of absenteeism, presenteeism, or burnout.
  • Foster an environment of open communication and dialogue to reduce mental health stigma — and lead by example from the top down.
  • Consider expanding your benefits to include access to quality treatments for mental health conditions so that you can address the root cause of their concerns.

Defining quality care

If you’re looking to add specialized mental health resources to your benefits package, it can be difficult to know where to start. Evaluating mental health solutions can feel overwhelming, given the number of self-help apps, coaching services, digital treatments, and wellness products available on the market today. Here are some important questions to consider:

  • Is it backed by science?
  • Does it offer a long-term solution or a short-term fix?
  • What does engagement look like?
  • Is it targeted towards specific conditions?
  • Does it deliver a strong ROI?

By offering solutions that are clinically validated, targeted, easy to use, engaging, and deliver long-term results in a short period of time, you’ll ensure your people have access to the quality care they deserve — and are fundamentally entitled to.

At Big Health, our mission is to help millions get back to good mental health. We’ve reached hundreds of thousands of people through our effective digital treatments for some of the most common mental health conditions, delivering up to a 4:1 ROI to the organizations we serve, and are steadfast in our goal to make mental health care accessible to all.

Learn more about how we can help you improve access to quality care in your organization.

1.  Rounded average ROI; Internal Data. (2023).

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

DOC-3367 Effective 10/2023

Subscribe to blog

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023